CEO exercised or converted 7,490 CYTK derivative securities | OQRO Insider tradesWhy it stands out
Derivative exercise or conversion — not an open-market buy.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell
All the details
Dates, kept separate
- Transaction date
- Jul 13, 2026
- Reporting period
- Not applicable
- Filed with the SEC
- Jul 14, 2026
CEOOption exercise
Context
- Classification
option exercise
Code M — exercise or conversion of a derivative security
- Planned / mechanical clue
None found in footnotes
Only flagged when a footnote says so; never inferred
Source receipt
- Record ID
- 0001061983-26-000077
Added to OQROOct 6, 2026, 7:14 PM UTC Data qualityVerified: identifiers matched exactly Reporting personRobert I Blum RelationshipDirector, Officer Officer titlePresident & CEO TableNon-derivative (Table I) Transaction dateJul 13, 2026 Acquired / disposedAcquired (A) Shares owned after385,310 Around the same time
Derivative exercise or conversion — not an open-market buy.
CEO sold ~$576K of Cytokinetics
Automatic saleDerivative exercise or conversion — not an open-market buy.